LRRK2-Targeting Oligonucleotides for RNA and Protein Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases, particularly Parkinson's disease, lack effective options, especially for non-LRRK2 mediated cases, and there is a need for compounds and methods to reduce LRRK2 RNA and protein levels to ameliorate symptoms such as ataxia, neuropathy, and aggregate formation.
Innovation Solution
Development of oligomeric compounds, including modified oligonucleotides, that specifically target and reduce LRRK2 RNA and protein levels in cells, utilizing complementary nucleobase sequences and modifications to enhance hybridization and activity reduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurodegenerative diseases are used, then existing therapeutic options are available, but effective treatment is lacking especially for non-LRRK2 mediated cases
Solution Approach 1:
The patent changes the molecular target parameter from traditional symptomatic treatments to LRRK2 RNA/protein reduction, enabling effective treatment across both LRRK2-mediated and non-LRRK2-mediated Parkinson's disease subtypes by addressing the underlying molecular mechanism rather than symptom-specific therapy
2Reliability
If LRRK2 expression is reduced using oligomeric compounds, then therapeutic benefits are achieved, but compound specificity and delivery challenges remain
Solution Approach 1:
The patent applies local quality by designing oligomeric compounds with specific nucleobase sequences that hybridize to particular regions of LRRK2 RNA, creating region-specific reduction of LRRK2 expression while maintaining overall therapeutic effect, thereby achieving precise molecular targeting
Solution Approach 2:
The patent uses modified oligonucleotides that copy the nucleic acid sequence information to guide selective reduction of LRRK2 RNA, allowing precise control over which protein isoforms are reduced based on the complementary sequence design
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively lower LRRK2 expression, leading to improved motor function, reduced neuropathy, and decreased aggregate formation, providing therapeutic benefits for both LRRK2 mediated and non-LRRK2 mediated Parkinson's disease.
Implementation Method 1
utilizing complementary nucleobase sequences and modifications to enhance hybridization and activity reduction
Data Source
AI summary
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of LRRK2 RNA in a cell or animal, and in certain instances reducing the amount of LRRK2 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include ataxia, neuropathy, and aggregate formation. Such neurodegenerative diseases include Parkinson's disease.